Sydney, July 11, 2007 (ABN Newswire) - Starpharma Holdings Limited (ASX: SPL) - US NIH Funded Trial of VivaGel Commences - Dr Jackie Fairley, CEO; Starpharma Holdings Limited (ASX: SPL) present the following audio webcast regarding "US NIH Funded Trial of VivaGel Commences". You may also download this audio webcast to your computer of portable audio player.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
News 
